Dr. Paul-Peter Tak is Senior Vice President and Head of the ImmunoInflammation Therapy Area Unit at GlaxoSmithKline, a role he assumed in 2011. He is also the Site Head of GSK Research & Development in Stevenage, U.K., Vice-Chair of GSK’s Scientific Review Board and Chair of EFPIA’s Research Directors Group. Professor Tak received his medical degree from the Free University in Amsterdam, the Netherlands graduating cumlaude. He trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, the Netherlands, where he also received his PhD. He worked as a visiting scientist at the School of Medicine at University of California, San Diego, La Jolla, USA, for 2 years and was affiliated with this university as clinical associate professor for a further 5 years. He has served as Professor of Medicine and Director of the Division of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam from 1999 until 2011. From 2004 to 2008 he also served as medical director of the Dubai Bone and Joint Center (Dubai, United Arab Emirates). In 2005 he founded Arthrogen B.V., a biotech company based in Amsterdam developing gene therapy. Professor Tak has been a member of the European League against Rheumatism(EULAR) Scientific Committee and Executive Committee and a member of the Annual Meeting Planning Committee of the American College of Rheumatology. He further acted as chairman of the EULAR Standing Committee on Investigative Rheumatology as well as chairman of the Grant Advisory Council for EULAR’s Orphan Disease Programme on systemic sclerosis. He has published more than 400 papers in international, peer-reviewed journals.